Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 6, 2009, Pages 553-556

  Sugiyama, Emiko ^a   Lee, Su Jun ^b   Lee, Sang Seop ^b   Kim, Woo Young ^b   Kim, Su Ryang ^a   Tohkin, Masahiro ^a   Hasegawa, Ryuichi ^a   Okuda, Haruhiro ^a   Kawamoto, Manabu ^c   Kamatani, Naoyuki ^c,d   Sawada, Jun ichi ^a,e   Kaniwa, Nahoko ^a   Saito, Yoshiro ^a   Shin, Jae Gook ^b  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b Inje University College of Medicine   (South Korea)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d Kuramae Orashion Bldg 9F   (Japan)

^e PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

Author keywords

Allele frequency; CDA; Ethnic difference; Non synonymous single nucleotide polymorphisms

Indexed keywords

ADENOSINE; CYTIDINE; CYTIDINE DEAMINASE; GUANIDINE;

ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN AMERICAN; CATALYSIS; ENZYME ACTIVITY; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; JAPANESE; KOREA; MALE; METABOLITE; NORMAL HUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

EID: 73349128135     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.553     Document Type: Article

References (12)

1. Maring, J. G., Groen, H. J., Wachters, F. M., Uges, D. R. and de Vries, E. G.: Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J., 5: 226-243 (2005).
2. Gilbert, J. A., Salavaggione, O. E., Ji, Y., Pelleymounter, L. L., Eckloff, B. W., Wieben, E. D., Ames, M. M. and Weinshilboum, R. M.: Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res., 12: 1794-1803 (2006).
3. Giovannetti, E., Laan, A. C., Vasile, E., Tibaldi, C., Nannizzi, S., Ricciardi, S., Falcone, A., Danesi, R. and Peters, G. J.: Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids, 27: 720-725 (2008).
4. Tibaldi, C., Giovannetti, E., Vasile, E., Mey, V., Laan, A. C., Nannizzi, S., Di Marsico, R., Antonuzzo, A., Orlandini, C., Ricciardi, S., Del Tacca, M., Peters, G. J., Falcone, A. and Danesi, R.: Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res., 14: 1797-1803 (2008).
5. Yue, L., Saikawa, Y., Ota, K., Tanaka, M., Nishimura, R., Uehara, T., Maeba, H., Ito, T., Sasaki, T. and Koizumi, S.: A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics, 13: 29-38 (2003).
6. Sugiyama, E., Kaniwa, N., Kim, S. R., Kikura-Hanajiri, R., Hasegawa, R., Maekawa, K., Saito, Y., Ozawa, S., Sawada, J., Kamatani, N., Furuse, J., Ishii, H., Yoshida, T., Ueno, H., Okusaka, T. and Saijo, N.: Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol., 25: 32-42 (2007).
7. Yonemori, K., Ueno, H., Okusaka, T., Yamamoto, N., Ikeda, M., Saijo, N., Yoshida, T., Ishii, H., Furuse, J., Sugiyama, E., Kim, S.R., Kikura-Hanajiri, R., Hasegawa, R., Saito, Y., Ozawa, S., Kaniwa, N., Sawada, J.: Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin. Cancer Res., 11: 2620-2624 (2005).
8. Kaniwa, N., Kurose, K., Jinno, H., Tanaka-Kagawa, T., Saito, Y., Saeki, M., Sawada, J., Tohkin, M. and Hasegawa, R.: Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686CÀT (P229L) found in an African-American. Drug Metab. Dispos., 33: 458-465 (2005).
9. Saeki, M., Saito, Y., Jinno, H., Tohkin, M., Kurose, K., Kaniwa, N., Komamura, K., Ueno, K., Kamakura, S., Kitakaze, M., Ozawa, S. and Sawada, J.: Comprehensive UGT1A1 genotyping in a Japanese population by pyrosequencing. Clin. Chem., 49: 1182-1185 (2003).
10. Yue, L. J., Chen, X. W., Li, C. R., Li, C. G., Shi, H. S. and Zhang, M.: Single-nucleotide polymorphisms of the cytidine deaminase gene in childhood with acute leukemia and normal Chinese children. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. (in Chinese), 24: 699-702 (2007).
11. Fukunaga, A. K., Marsh, S., Murry, D. J., Hurley, T. D. and McLeod, H. L.: Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J., 4: 307-314 (2004).
12. Ueno, H., Kaniwa, N., Okusaka, T., Ikeda, M., Morizane, C., Kondo, S., Sugiyama, E., Kim, S. R., Hasegawa, R., Saito, Y., Yoshida, T., Saijo, N. and Sawada, J.: Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br. J. Cancer, 100: 870-873 (2009).